The pediatric short bowel syndrome and intestinal failure clinic nurse’s communication challenge
Short bowel syndrome in children is not a single event. It is a years-long trajectory that begins in the operating room — often in the hours after birth — and continues through an intensive period of intestinal rehabilitation whose endpoint cannot be predicted at the start. The child with gastroschisis who loses most of her small bowel to mid-gut volvulus at 36 hours of life, the premature infant who requires three separate resections for necrotizing enterocolitis at 28 weeks, the newborn with apple-peel jejunal atresia who arrives in the NICU with 18 centimeters of intestine: these children leave the hospital dependent on a catheter that delivers nutrition directly into a large central vein, a pump that runs for 16 to 20 hours a day, and a clinical team that monitors absorptive capacity, liver function, central line infections, and growth trajectory week by week and month by month for years.
The families who live this trajectory do so with extraordinary dedication. They learn central line care, they log feeds and urine output, they learn to mix and hang TPN solutions or to accept home nursing visits to do it. They watch their child grow in a context where “growing well” is not a given but a daily achievement that requires a mechanical system, a clinical team, and their own attention. Over time, as the child begins to accept oral feeds, as growth improves, as the TPN hours are slowly reduced, families develop a natural and understandable hope: that the child is getting better, that the condition is resolving, that the end of TPN is near and the beginning of a normal childhood is arriving.
That hope — well-founded in the long trajectory and accurate in its general direction — is the source of the most consequential misunderstandings in the pediatric intestinal failure clinic. The father who sees his infant take a few milliliters of breast milk by mouth for the first time and concludes that TPN is no longer needed. The grandmother who removes the central venous catheter because she does not trust it, and believes the gastrostomy tube or a regular IV is a sufficient substitute. The mother who sees the bilirubin fall to near-normal on the lab report and concludes that the liver disease is resolved and the protective medication can be stopped.
In each case the family has observed a real positive change. In each case the conclusion drawn from that change is wrong in a way that creates immediate danger: the infant whose TPN is stopped will not absorb sufficient calories from a 15-centimeter bowel that has not yet adapted; the child whose Broviac is removed has no access for the nutrition that cannot be given peripherally; the child whose UDCA is stopped while PN continues has lost hepatic protection from a mechanism that is still operating. The nurse in the intestinal failure clinic has a narrow window — typically a monthly or bimonthly visit, sometimes a phone call, sometimes a message through the patient portal — to make the distinction between what the positive change means and what it does not mean, in Spanish, clearly enough that the family can carry it home and use it in the days when the temptation to stop the treatment returns.
Three misalignments recur with particular frequency and consequence in this clinic when the family is Spanish-speaking and the mechanism behind the treatment has not been explained in their language or their conceptual frame.
The first is the oral-feeding-means-TPN-is-unnecessary misconception. The connection between eating and growing seems universal and obvious. What the family does not have is a mental model of intestinal adaptation as a biological process with a measurable timeline, and of the relationship between the length of remaining bowel, the absorptive capacity of that bowel at a given point in adaptation, and the caloric gap that TPN is filling. Making that model accessible in Spanish — without medical jargon, without losing the precision — is the nurse’s work.
The second is the catheter-versus-feeding-tube equivalence misunderstanding. Families managing a child with a gastrostomy, a Broviac, and sometimes a nasogastric tube are managing three separate access devices. The idea that these might substitute for one another feels logical — nutrition goes in, why does it matter which tube? The answer involves the chemistry of TPN solutions and the physiology of vascular endothelium, neither of which is intuitive, and both of which need to be explained in practical terms the family can remember and apply.
The third is the bilirubin-normalized-so-the-liver-is-better misunderstanding about what ursodeoxycholic acid is doing and what the bilirubin level is measuring. The relationship between a lab value, the disease process driving that value, and the protective mechanism that is counteracting it is not obvious to any non-clinician, and in Spanish-speaking families who received their initial IFALD explanation in English with a telephone interpreter, the mechanistic chain is often partially or entirely missing.
Three conversations from the pediatric intestinal failure clinic:
Scenario 1: Alejandro Vásquez-Reyes — 8 months old, Houston, Texas
Alejandro Vásquez-Reyes had been born at 38 weeks and two days with gastroschisis — a full-thickness defect in the right side of the abdominal wall through which a loop of small bowel had herniated into the amniotic fluid for much of the third trimester, exposed to the mechanical and chemical injury that bowel sustains without the protection of the abdominal wall and peritoneum. The bowel had been thickened, matted with a fibrous peel, and shortened from the chronic inflammation. The neonatologist had prepared Carlos Vásquez-Morales and his wife Elena at 34 weeks, when the prenatal ultrasound showed the dilated bowel loops outside the abdomen with thick walls and sluggish peristalsis. “Complex gastroschisis,” the neonatologist had said. “He may need surgery on the intestine itself after we close the abdomen.”
What Carlos and Elena had not been told, because no one could predict it prenatally, was that Alejandro would develop a mid-gut volvulus — a twisting of the intestinal mesentery — during the first attempted silo reduction at 48 hours of life. The volvulus had been acute, causing ischemia in the segment that had twisted. The pediatric surgeon had opened the abdomen, found necrotic bowel from the ligament of Treitz to the mid-transverse colon, and resected it. Alejandro had emerged from surgery with 15 centimeters of small bowel remaining from the proximal jejunum, his duodenum intact, and a jejuno-colonic anastomosis.
Carlos had been told the length. He had not fully understood what it meant until the surgeon sat with him and a Spanish-language interpreter and explained, slowly and carefully, that a normal adult small bowel is approximately 600 centimeters long, that Alejandro had 15 centimeters, and that Alejandro would receive all of his nutrition through the vein for the foreseeable future — months, possibly years — while the remaining bowel underwent a process of adaptation.
Carlos had nodded. He had gone home and looked up “intestino corto” on his phone for four hours. He had joined a Facebook group for parents of children with short bowel syndrome. He had watched his son through the NICU glass for three months before Alejandro came home with a Broviac catheter, a home TPN program running 18 hours nightly, a pump the size of a small backpack, and a home nursing agency that came three times a week to change the line dressing and review the TPN rate.
Carlos had done everything right for six months. He had kept the log. He had attended every clinic visit. He had brought the dressing change supplies to a birthday party and done the change in the car without complaint. He had learned to program the pump and to troubleshoot the alarms. He was a construction foreman, and he had applied the same methodical attention he gave to a structural project to the management of his son’s nutritional support.
Now, at the eight-month visit, Alejandro had done something new. Three weeks ago, the occupational therapist had placed a small amount of expressed breast milk on a spoon and touched it to Alejandro’s lower lip. Alejandro had extended his tongue. The next session, he had taken half a teaspoon from the spoon. Now, three weeks later, he was accepting 15 to 20 milliliters of breast milk per feed, three feeds per day, by mouth — the first oral intake of his life.
Carlos sat across from the intestinal failure nurse, Elena Morales-Fuentes, with Alejandro in his lap, the infant mouthing a soft teething ring with considerable determination. Carlos was smiling, but there was something behind the smile.
“Ya está comiendo,” Carlos said. “Tres veces al día. Ya no parece que necesite la nutrición de la vena.” (He is eating now. Three times a day. He no longer seems to need the nutrition from the vein.)
Elena looked at Alejandro, who was studying the teething ring with complete absorption, and then back at Carlos. “Es una noticia excelente. Tres semanas tomando leche por la boca — eso es exactamente lo que queremos ver.” (That is excellent news. Three weeks taking milk by mouth — that is exactly what we want to see.)
“Entonces ¿podemos quitar la nutrición intravenosa?” (So can we remove the intravenous nutrition?)
“Todavía no. Le explico por qué, y quiero que lo entienda bien, porque es importante.” Elena leaned slightly forward. (Not yet. I will explain why, and I want you to understand it well, because it is important.)
“El intestino de Alejandro está pasando por un proceso que se llama adaptación intestinal. Cuando queda poco intestino después de una cirugía, el intestino que queda empieza a cambiar — las células que absorben los nutrientes crecen más altas, los pliegues se hacen más gruesos, la pared se hace más grande por dentro. Es como si el intestino estuviera entrenando para hacer el trabajo de un intestino más largo. Ese proceso tarda de uno a tres años.” (Alejandro’s intestine is going through a process called intestinal adaptation. When little intestine remains after surgery, the remaining intestine starts to change — the cells that absorb nutrients grow taller, the folds become thicker, the inner wall becomes larger. It is as if the intestine is training to do the work of a longer intestine. That process takes one to three years.)
Carlos nodded slowly. “Eso sí lo sabía. El grupo de padres me lo dijo.” (I did know that. The parent group told me.)
“Bien. Lo que quizás no está tan claro es cuánto puede absorber el intestino de Alejandro ahora mismo, con ocho meses de adaptación.” Elena picked up a pen and turned to the paper on the exam table. “Alejandro necesita — con su peso actual de 7.2 kilos — alrededor de 720 calorias al día para crecer bien. Eso es lo mínimo. Idealmente 750 a 800.” (Good. What may not be as clear is how much Alejandro’s intestine can absorb right now, at eight months of adaptation. Alejandro needs — at his current weight of 7.2 kilograms — around 720 calories per day to grow well. That is the minimum. Ideally 750 to 800.)
“¿Y cuántas calorias le da la leche que toma?” (And how many calories does the milk he takes give him?)
“La leche materna tiene aproximadamente 20 calorías por cada 30 mililitros. Alejandro toma 15 a 20 mililitros, tres veces al día. Eso es 45 a 60 mililitros totales al día. Si absorbiera todo — lo cual no ocurre en 15 centímetros de intestino en adaptación — serían 30 a 40 calorías. De las 720 que necesita.” She wrote the numbers on the paper: 720 at the top, 30–40 at the bottom, and drew a line between them. (Breast milk has approximately 20 calories per 30 milliliters. Alejandro takes 15 to 20 milliliters, three times a day. That is 45 to 60 milliliters total per day. If he absorbed everything — which does not happen in 15 centimeters of intestine in adaptation — that would be 30 to 40 calories. Out of the 720 he needs.)
Carlos looked at the numbers. “Las otras… 680 calorías…”
“Vienen de la nutrición intravenosa. Eso es lo que la nutrición de la vena está haciendo ahora mismo: llenando ese espacio.” (Come from the intravenous nutrition. That is what the nutrition from the vein is doing right now: filling that space.)
Carlos looked at Alejandro, who had dropped the teething ring and was reaching for Carlos’s watch. “¿Y la leche que está tomando sirve de algo, entonces?” (And does the milk he is taking serve any purpose, then?)
“Sirve para algo muy importante. El contacto de la leche con el intestino es el estímulo que acelera la adaptación. Las mismas células del intestino — cuando reciben leche, cuando tienen qué absorber — mandan señales que les dicen a otras células que crezcan. Es como el ejercicio para el músculo: el intestino se hace más fuerte porque tiene que trabajar.” (It serves something very important. The contact of the milk with the intestine is the stimulus that accelerates adaptation. The intestinal cells themselves — when they receive milk, when they have something to absorb — send signals that tell other cells to grow. It is like exercise for a muscle: the intestine becomes stronger because it has to work.)
“¿Entonces — la leche que toma es lo que hace que eventualmente podamos quitar la nutrición de la vena?” (So — the milk he takes is what will eventually allow us to stop the intravenous nutrition?)
“Exactamente. La alimentación oral es el ejercicio que entrena al intestino. La nutrición intravenosa es lo que alimenta a Alejandro mientras su intestino se entrena. Los dos trabajan juntos. No son sustituibles — los dos son necesarios en este momento.” (Exactly. The oral feeding is the exercise that trains the intestine. The intravenous nutrition is what feeds Alejandro while his intestine trains. The two work together. They are not substitutable — both are necessary at this moment.)
Carlos picked up the teething ring from the floor and handed it to Alejandro. “¿Cuándo podremos empezar a bajar las horas?” (When will we be able to start reducing the hours?)
“Cuando el crecimiento de Alejandro se mantenga bien con más calorias entrerales y menos intravenosas. Eso lo medimos en cada visita — el peso, la talla, los estudios de absorción. El siguiente paso, si sigue aumentando bien el volumen oral, sería bajar de 18 horas a 16 horas al mes próximo y ver cómo crece. Cada reducción es una prueba, no una decisión definitiva. Si Alejandro crece bien a 16 horas, lo bajamos a 14. Y así.” (When Alejandro’s growth remains good with more enteral and less intravenous calories. We measure that at each visit — weight, height, absorption studies. The next step, if oral volume keeps increasing, would be to reduce from 18 hours to 16 hours next month and see how he grows. Each reduction is a trial, not a final decision. If Alejandro grows well at 16 hours, we reduce to 14. And so on.)
Carlos folded the piece of paper with Elena’s numbers and put it in his phone case. “De acuerdo,” he said. “Entonces que tome todo lo que quiera.” (All right. Then let him take as much as he wants.)
“Todo lo que quiera,” Elena confirmed. “Eso es exactamente lo correcto.” (As much as he wants. That is exactly right.)
Scenario 2: Sofía Torres-Espinoza — 3 years old, San Antonio, Texas
Sofía Torres-Espinoza had been born at 28 weeks and five days at University Hospital San Antonio, the fourth premature birth in her family — two of her older siblings had been born early without lasting complication, and her mother Marta had approached the pregnancy with cautious optimism that did not prepare her for what happened in the second week of Sofía’s life. On day nine, Sofía’s feeding was interrupted: her belly was distended, her residuals were bloody, and an abdominal X-ray showed the pneumatosis intestinalis — air in the bowel wall — that is the radiographic signature of necrotizing enterocolitis. The NEC progressed despite maximal medical management. By day twelve, Sofía had required three separate laparotomies to resect necrotic segments. When the surgeon finally closed the abdomen on the third operation, Sofía had 22 centimeters of small bowel remaining, with her ileocecal valve intact — a significant advantage in intestinal adaptation outcomes — and an ileo-colonic anastomosis.
Marta had spent four months in the NICU learning everything the team taught her: how to manage the Broviac central venous catheter, how to set up and monitor the TPN pump, how to draw blood cultures at the first sign of fever, how to troubleshoot line occlusion alarms. She was twenty-seven years old and she had absorbed the education with the fierce focus of a person who understood that her daughter’s survival depended on what she knew.
What Marta had not anticipated was the complexity of childcare coverage when she returned to work. Marta was a hospital billing specialist; she worked a 40-hour week. Sofía’s care required someone present during TPN infusion, which ran 20 hours a day. The solution was Sofía’s paternal grandmother, Rosa Torres-Cisneros, who retired from her job at a dry-cleaning business to provide full-time daytime care for Sofía.
Rosa loved Sofía with a ferocity that made her exceptionally good at most aspects of her care. She was meticulous about the TPN schedule, she documented feeds and outputs accurately, and she transported Sofía to therapy appointments and clinic visits with the reliability of a well-managed transportation service. What Rosa had not absorbed — because the explanation had been given to Marta in the NICU using an interpreter, and Rosa had not been present for those sessions, and the subsequent home nursing visits had focused on procedure rather than mechanism — was why the Broviac was necessary. She knew it was used for nutrition. She did not know what would happen if it were replaced.
The nurse at the intestinal failure clinic, Patricia Herrera-Cisneros, reviewed the home nursing note from the prior week and then reviewed Sofía’s TPN record. There was a seven-day gap in the TPN record. Sofía was sitting on the exam table drawing with a crayon, apparently unaffected, but her weight was 0.3 kilograms below her trajectory.
“Hay un lapso de siete días en el registro de la nutrición,” Patricia said to Marta, who had taken the morning off from work to attend the visit. “¿Qué pasó?” (There is a seven-day gap in the nutrition record. What happened?)
Marta looked at Rosa. Rosa looked at her hands.
“Yo lo quite,” Rosa said quietly. “El catéter. Estaba asustada. La niña siempre lo jala, una tarde vi que estaba un poco salido de su lugar, y pensé que era mejor quitarlo antes de que se infectara. Ella tiene el gastrostoma y la vía normal — le pusimos la nutrición por ahí.” (I removed it. The catheter. I was frightened. The child always pulls at it, one afternoon I saw it was a little out of place, and I thought it was better to remove it before it got infected. She has the gastrostomy and a regular IV — we put the nutrition through those.)
Patricia was quiet for a moment. She looked at Sofía, who was drawing what appeared to be a horse with six legs on a yellow piece of paper, with the complete concentration of a three-year-old doing something important.
“Rosa, gracias por contarme. Necesito explicarle algo sobre la nutrición de Sofía que es muy importante. ¿Puedo?” (Rosa, thank you for telling me. I need to explain something about Sofía’s nutrition that is very important. May I?)
“Sí.”
“La nutrición que Sofía recibe por la vena — la que va por el catéter — y la nutrición que recibe por el gastrostoma son dos cosas completamente diferentes. No son intercambiables. Voy a explicarle por qué.” (The nutrition Sofía receives through the vein — the one that goes through the catheter — and the nutrition she receives through the gastrostomy are two completely different things. They are not interchangeable. I will explain why.)
“La nutrición que va al gastrostoma de Sofía entra al estómago y de ahí al intestino. El intestino de Sofía tiene 22 centímetros — solo puede absorber una parte de lo que le entra. El resto sale sin ser absorbido. Entonces lo que entra por el gastrostoma ayuda, pero no es suficiente para darle a Sofía todo lo que necesita.” (The nutrition that goes into Sofía’s gastrostomy enters the stomach and from there the intestine. Sofía’s intestine has 22 centimeters — it can only absorb a portion of what enters it. The rest exits without being absorbed. So what goes through the gastrostomy helps, but it is not enough to give Sofía everything she needs.)
Rosa nodded. “Eso lo entendí. Por eso le pusimos también la vía intravenosa del brazo.” (I understood that. That is why we also put in the intravenous line in her arm.)
Patricia paused. “¿Qué le pusieron por esa vía?” (What did you put through that line?)
Rosa looked uncertain. “La misma solución. La que viene en las bolsas.” (The same solution. The one that comes in the bags.)
Patricia felt the particular clarity that comes with understanding what happened. “Rosa, escúcheme con cuidado.” (Rosa, listen to me carefully.)
“La solución de nutrición parenteral — la que está en las bolsas de Sofía — tiene una concentración muy, muy alta. Es como azúcar pura disuelta en agua, más aminoácidos, más grasas, más minerales — todo concentrado en un volúmen pequeño para que entre bien por la vena. La concentración de esa solución es cinco veces más alta que la concentración de la sangre.” (The parenteral nutrition solution — the one in Sofía’s bags — has a very, very high concentration. It is like pure sugar dissolved in water, plus amino acids, plus fats, plus minerals — all concentrated in a small volume so it enters well through the vein. The concentration of that solution is five times higher than the concentration of blood.)
Rosa had gone very still. “¿Y eso…?”
“Cuando esa solución entra por una vena pequeña — como la del brazo — quema la pared de la vena. No metafóricamente. Literálmente. La diferencia de concentración entre la solución y las células de la pared de la vena hace que esas células pierdan agua rápidamente y mueran. Eso produce inflamación, coagulación, y si la solución se sale de la vena al tejido que la rodea — produce quemaduras químicas en la piel y el tejido debajo de ella.” (When that solution enters through a small vein — like the one in the arm — it burns the wall of the vein. Not metaphorically. Literally. The concentration difference between the solution and the cells of the vein wall causes those cells to lose water rapidly and die. That produces inflammation, clotting, and if the solution escapes from the vein into the surrounding tissue — it produces chemical burns in the skin and tissue beneath it.)
Marta had covered her mouth. “¿Sofía tiene quemaduras?” (Does Sofía have burns?)
“Necesito revisar el brazo ahora mismo.” Patricia moved to the exam table. “Sofía, ¿puedo ver tu brazo?” (I need to check the arm right now. Sofía, may I see your arm?)
Sofía extended both arms without looking up from the horse drawing. The right arm showed residual redness at the antecubital fossa and a 2-centimeter area of indurated skin below the antecubital fold consistent with a resolving extravasation injury. No open wound. Patricia photographed it and made a note.
“Hay una zona donde la solución se salió al tejido. Está mejorando sola — no hay herida abierta — pero eso es exactamente lo que pasa cuando la nutrición parenteral entra por una vena pequeña.” (There is a zone where the solution escaped into the tissue. It is healing on its own — there is no open wound — but that is exactly what happens when parenteral nutrition enters through a small vein.)
She turned to Rosa. “El catéter de Sofía — el Broviac — está colocado quirúrgicamente, con la punta en una vena grande, cerca del corazón, donde la sangre corre muy rápido. Cuando la solución entra ahí, la sangre la diluye casi instantáneamente y la concentración baja a niveles seguros antes de que llegue a la pared de ninguna vena. Eso es por qué se necesita ese catéter específico. No hay ninguna vena del brazo, la mano, o el pie que pueda recibir esta solución sin dañarse.” (Sofía’s catheter — the Broviac — is placed surgically, with the tip in a large vein, near the heart, where blood flows very fast. When the solution enters there, the blood dilutes it almost instantly and the concentration drops to safe levels before it reaches the wall of any vein. That is why that specific catheter is needed. There is no vein in the arm, hand, or foot that can receive this solution without damage.)
Rosa was quiet for a long moment. “¿Y estos siete días sin la nutrición correcta — le hizo daño?” (And these seven days without the correct nutrition — did it cause harm?)
“Su peso está un poco por debajo de donde debería estar — bajó 300 gramos de la curva. Lo recuperamos rápidamente una vez que reestablecemos el acceso. Vamos a hablar con el equipo quirúrgico hoy para programar la colocación de un nuevo Broviac esta semana.” (Her weight is a little below where it should be — she dropped 300 grams from the curve. We recover that quickly once we re-establish access. We are going to talk with the surgical team today to schedule placement of a new Broviac this week.)
Rosa looked at Sofía, who had added a seventh leg to the horse and appeared pleased. “Cuando vi que estaba un poco salido, me asusté. No sabía que quitarlo era peor que dejarlo.” (When I saw it was a little out of place, I was frightened. I did not know that removing it was worse than leaving it.)
“Si vuelve a ver que el catéter está salido o en una posición diferente, llámeme antes de hacer nada. Tenemos una línea de emergencia. Hay cosas que hacer que no incluyen quitarlo.” Patricia said this clearly and without judgment. “Nadie le enseñó eso, y ahora usted lo sabe.” (If you see again that the catheter is out of place or in a different position, call me before doing anything. We have an emergency line. There are things to do that do not include removing it. Nobody taught you that, and now you know it.)
Rosa nodded once. She looked at Marta. Marta reached across and held her hand.
Scenario 3: Marco García-Hernández — 5 years old, Dallas, Texas
Marco García-Hernández had arrived at Children’s Medical Center Dallas on the day of his birth, transferred by ambulance from a community hospital where a routine prenatal ultrasound at 36 weeks had found a dilated, aperistaltic loop of bowel above a point where no continuity was visible. The prenatal diagnosis had been jejunal atresia. The postnatal reality, on laparotomy at 6 hours of life, was a Type 3B apple-peel atresia — the most severe variant, in which the jejunum beyond the atresia point is absent and the remaining small bowel spirals in a loose helix around its vascular supply like a coiled spring, the mesentery perforated and incomplete, the bowel wall thin and fragile. The surgeon had resected the malformed segment and found 18 centimeters of usable small bowel, with no ileocecal valve.
Marco had been on parenteral nutrition for four years and two months by the time of his fifth birthday. He had had four Broviac revisions, eleven line-associated bloodstream infections over that time, two episodes of cholestatic jaundice severe enough to require inpatient management, and one hospitalization for d-lactic acidosis from small bowel bacterial overgrowth. He had also had, in the past eighteen months, a sustained improvement: the transition from soy-based Intralipid to a fish-oil-based lipid emulsion (SMOFlipid) had reduced the phytosterol load to his liver, the introduction of oral cycling with amino acid-based formula had increased his enteral tolerance to six hours per day, and the addition of ursodeoxycholic acid 15 mg/kg/day had been associated with a fall in his total bilirubin from 4.2 mg/dL to 1.8 mg/dL over eight months.
His mother Lucía García-Espinoza was a medical assistant at a dermatology practice. She had spent five years becoming literate in the management of Marco’s condition in ways that most parents of children with SBS never achieve: she understood intestinal adaptation, she tracked his growth curves, she knew the difference between D-lactate and L-lactate on a blood gas. What she lacked — because the mechanism of IFALD had been explained to her twice in English, with a telephone interpreter whose interpretation she found difficult to follow, during hospitalizations when she was sleep-deprived and frightened — was a clear model of why ursodeoxycholic acid was doing what it was doing.
The intestinal failure nurse, Diana Torres-Reyes, reviewed Marco’s lab trend at the beginning of the clinic visit. The total bilirubin, which had been 1.8 mg/dL at the last visit, was now 2.4 mg/dL. It had been climbing for six weeks.
“La bilirrubina subió,” Diana said, looking at the trend. “Quiséra entender por qué. ¿Hubo algún cambio en los medicamentos en las últimas semanas?” (The bilirubin went up. I would like to understand why. Were there any changes in medications in the last few weeks?)
Lucía had been expecting the question. “Le quité el UDCA hace un mes. La bilirrubina estaba en 1.8 y pensé que el hígado ya estaba bien. No quería darle más cosas de las que ya tiene.” (I stopped the UDCA a month ago. The bilirubin was 1.8 and I thought the liver was already well. I did not want to give him more things than he already has.)
Diana closed the chart and turned to face Lucía directly. “Gracias por contarme. Eso explica la tendencia. Voy a explicarle lo que el UDCA está haciendo, porque creo que la explicación que tiene no es completa, y con la explicación completa, la decisión tiene más sentido.” (Thank you for telling me. That explains the trend. I am going to explain what UDCA is doing, because I believe the explanation you have is not complete, and with the complete explanation, the decision makes more sense.)
Lucía crossed her arms and looked at Diana with the attentiveness of someone who has learned, through five years of managing a complex medical child, that explanations matter and that incomplete ones cause harm.
“La enfermedad del hígado que tiene Marco — la que se llama IFALD — está causada por la nutrición intravenosa en sí misma. No es una enfermedad que Marco tuvo y que se curó. Es una presión continua sobre el hígado que ocurre porque Marco necesita la nutrición intravenosa. Mientras Marco reciba nutrición parenteral, esa presión existe. Cuando la bilirrubina bajó a 1.8, eso significó que el UDCA y el cambio al SMOFlipid estaban protegiendo el hígado de esa presión. No que la presión desapareció.” (The liver disease Marco has — the one called IFALD — is caused by the intravenous nutrition itself. It is not a disease Marco had and that was cured. It is a continuous pressure on the liver that occurs because Marco needs intravenous nutrition. As long as Marco receives parenteral nutrition, that pressure exists. When the bilirubin fell to 1.8, that meant the UDCA and the switch to SMOFlipid were protecting the liver from that pressure. Not that the pressure disappeared.)
Lucía uncrossed her arms. “¿Cómo es que la nutrición le hace eso al hígado?” (How does the nutrition do that to the liver?)
“Por varias razones que actúan juntas. Primera: las soluciones de grasa que usamos en la nutrición intravenosa contienen sustancias llamadas fitoesteroles — son como una versión vegetal del colesterol. El hígado humano no puede procesarlos bien, y se acumulan en las células del hígado y las dañan. El SMOFlipid tiene muchos menos fitoesteroles que las soluciones de grasa que usábamos antes — por eso lo cambiamos.” (For several reasons that act together. First: the fat solutions we use in intravenous nutrition contain substances called phytosterols — they are like a plant version of cholesterol. The human liver cannot process them well, and they accumulate in liver cells and damage them. SMOFlipid has far fewer phytosterols than the fat solutions we used before — that is why we switched.)
“Segunda: cuando hay poca o ninguna alimentación oral, el cuerpo produce menos de una hormona que se llama colecistoquinina — CCK. La CCK es la señal que le dice a la vesícula biliar que se contraiga y libere bilis hacia el intestino. Cuando hay poca CCK, la bilis se queda quieta en el hígado y los conductos biliares — se estanca. La bilis estancada es tóxica para los conductos y las células del hígado. Eso se llama colestasis.” (Second: when there is little or no oral feeding, the body produces less of a hormone called cholecystokinin — CCK. CCK is the signal that tells the gallbladder to contract and release bile into the intestine. When there is little CCK, bile stays still in the liver and bile ducts — it stagnates. Stagnated bile is toxic to the ducts and liver cells. That is called cholestasis.)
“Tercera: la nutrición intravenosa sin alimentación oral produce cambios en las bacterias del intestino de Marco. Esas bacterias producen sustancias que pasan a la sangre y llegan al hígado y lo inflaman. Y cuarta: cada infección del catéter — y Marco ha tenido once en cuatro años — produce inflamación que llega directo al hígado.” (Third: parenteral nutrition without oral feeding produces changes in Marco’s intestinal bacteria. Those bacteria produce substances that pass into the blood and reach the liver and inflame it. And fourth: each catheter infection — and Marco has had eleven in four years — produces inflammation that reaches directly to the liver.)
Lucía was listening very carefully. “¿Y el UDCA?” (And the UDCA?)
“El UDCA es un ácido biliar — una sustancia que está naturalmente en pequeñas cantidades en la bilis de todos nosotros. Cuando Marco lo toma en dosis farmacológicas, esa sustancia se convierte en el ácido biliar principal de su bilis. ¿Por qué importa eso? Porque los ácidos biliares normales — los que produce el hígado sin ayuda — son tóxicos para las células de los conductos biliares cuando se estancan. El UDCA es mucho menos tóxico. Al reemplazar los ácidos biliares dañinos con UDCA, la bilis estancada en el hígado de Marco hace mucho menos daño que si estuviera compuesta de ácidos biliares normales.” (UDCA is a bile acid — a substance naturally present in small amounts in the bile of all of us. When Marco takes it in pharmacological doses, that substance becomes the main bile acid in his bile. Why does that matter? Because normal bile acids — those the liver produces without help — are toxic to the cells of the bile ducts when they stagnate. UDCA is much less toxic. By replacing the damaging bile acids with UDCA, the stagnated bile in Marco’s liver causes much less damage than if it were composed of normal bile acids.)
“Además, el UDCA mejora el flujo de la bilis — ayuda a que no se estanque tanto. Y protege las células del hígado de las señales que les dicen que mueran, que vienen de los ácidos biliares tóxicos. Son tres mecanismos que trabajan juntos, y los tres siguen siendo necesarios mientras la nutrición parenteral siga.” (Additionally, UDCA improves bile flow — it helps it not stagnate as much. And it protects liver cells from the signals that tell them to die, which come from toxic bile acids. Those are three mechanisms working together, and all three continue to be necessary as long as parenteral nutrition continues.)
Lucía was quiet for a moment. “Entonces la bilirrubina 1.8 era el UDCA funcionando, no el hígado curado.” (So the bilirubin 1.8 was the UDCA working, not the liver cured.)
“Exactamente. Y la bilirrubina 2.4 de hoy es el UDCA faltando, con la misma presión de la nutrición parenteral sobre el hígado que existió siempre.” (Exactly. And today’s bilirubin of 2.4 is the UDCA missing, with the same pressure from parenteral nutrition on the liver that always existed.)
Marco, who had been sitting on the exam table examining a stethoscope he had found in the supply pocket on the wall with the focus of someone planning to ask important questions about it, looked up. “¿Mi hígado está mal?” (Is my liver bad?)
“Tu hígado está trabajando muy duro,” Diana said, “y la medicina que tomas le ayuda a no cansarse tanto. Volvemos a dársela y el hígado va a estar mejor.” (Your liver is working very hard, and the medicine you take helps it not get as tired. We give it back and the liver will be better.)
Marco nodded, apparently satisfied, and returned to the stethoscope.
Lucía looked at Diana. “¿Cuándo va a poder parar la nutrición parenteral?” (When will he be able to stop parenteral nutrition?)
“La meta para Marco es la autonomía enteral — llegar a un punto en que el intestino absorba suficiente para no necesitar la nutrición intravenosa. Con 18 centimetros sin válvula ileocecal, la autonomía enteral es posible en algunos pacientes pero tarda más. Estamos en el camino correcto — seis horas de alimentación enteral al día es un avance real desde el año pasado. El intestino está adaptando. Mientras lo hace, el UDCA es lo que protege el hígado durante ese camino.” (The goal for Marco is enteral autonomy — reaching a point where the intestine absorbs enough not to need intravenous nutrition. With 18 centimeters without ileocecal valve, enteral autonomy is possible in some patients but takes longer. We are on the right path — six hours of enteral feeding per day is real progress from last year. The intestine is adapting. While it does, UDCA is what protects the liver during that journey.)
Lucía picked up her pen and wrote in the small notebook she brought to every visit: UDCA = protección durante la NP. Bilirrubina normal = UDCA funcionando. Bilirrubina alta = UDCA faltando. (UDCA = protection during PN. Normal bilirubin = UDCA working. High bilirubin = UDCA missing.)
“Empezamos de nuevo esta tarde,” she said. (We start again this afternoon.)
What these three conversations share
The pediatric intestinal failure clinic is organized around a biological truth that resists easy communication: the treatments keeping these children alive and growing are not treating a condition that has ended; they are supporting a process — intestinal adaptation — that is ongoing and has its own timeline, while simultaneously managing complications of the treatment itself. The TPN that feeds Alejandro is also straining the liver. The Broviac that delivers Sofia’s nutrition is also a portal for infection. The UDCA that protects Marco’s liver is the pharmacological compensation for a hepatic mechanism that the TPN itself is suppressing. The system is complex, interdependent, and invisible in the ways that matter most: the intestine does not send a notification when adaptation has advanced enough to reduce TPN hours; the liver does not display its condition through any external sign that a family can observe; the vein does not warn before the hyperosmolar solution begins to destroy it.
The families in these three scenarios are not careless. Carlos Vásquez-Morales has managed a Broviac in a wriggling eight-month-old for six months with perfect care. Rosa Torres-Cisneros retired from her job to provide daytime care for a three-year-old with a central line, a pump, and a gastrostomy, and when she acted, she acted from concern for Sofía’s safety. Lucía García-Hernández has spent five years developing an understanding of her son’s condition that far exceeds what most parents achieve. Their misunderstandings are not failures of attention. They are failures of information — specifically, of mechanistic information delivered in a language and conceptual frame the family can hold and use.
The specific failure in each case follows a common structure. A visible positive marker — a few milliliters of milk taken by mouth, a functioning regular IV, a bilirubin number that is back in range — is interpreted as evidence that the invisible protective mechanism is no longer necessary. The marker has improved; therefore the treatment is complete; therefore it can stop. What the family does not have is the information that would allow them to correctly evaluate what the marker is measuring: that oral feeds are stimulating intestinal adaptation but have not yet produced absorptive capacity; that central venous access is physically necessary for TPN delivery and has no substitute; that bilirubin normalization is a consequence of successful hepatoprotection that stops when the hepatoprotective agent stops.
In Spanish-speaking families navigating an intestinal failure program, the challenge is compounded by the fact that the initial explanations — delivered in the NICU during acute crisis, through interpreters on phones, in a register calibrated for English-speaking parents with more medical background — often reach only one caregiver, and often only partially. The grandmother who becomes the primary daytime caregiver after the mother returns to work inherits a complex medical routine but not always the mechanistic knowledge that makes the routine intelligible. The mother who has been managing for five years and has learned more than most has done so without the specific IFALD explanation because it was given twice in conditions where retention was impossible.
The intestinal failure nurse’s work is not repetition of discharge instructions. It is the construction, in Spanish, in clinical language that the family can carry away and use, of a correct mechanistic model of what each treatment is actually doing — and what will happen if it stops. That model is what Carlos needed to understand why oral feeds and TPN run in parallel, not in sequence. It is what Rosa needed to understand why the Broviac cannot be substituted. It is what Lucía needed to understand why bilirubin normalization is proof of protection working, not proof of protection no longer needed.
For related clinical conversations in adjacent specialties, see our posts on Spanish for pediatric gastroenterology clinic nurses, Spanish for pediatric liver disease clinic nurses, Spanish for pediatric surgery nurses, and Spanish for pediatric NICU follow-up clinic nurses.